Thermo Fisher Scientific, a company serving science, has announced a definitive agreement to acquire Solventum’s Purification & Filtration business for $4.1 billion in cash. Solventum’s division specializes in purification and filtration technologies used in biologics production, medical technologies, and industrial applications. With approximately 2,500 employees and operations spanning multiple regions, the business generated around $1 billion in revenue in 2024. The acquisition complements Thermo Fisher’s existing bioproduction capabilities, particularly in cell culture media and single-use technologies, expanding its offerings in both upstream and downstream workflows. The transaction is expected to close by the end of 2025, pending regulatory approvals and customary closing conditions, after which the business will be integrated into Thermo Fisher’s Life Sciences Solutions segment.
Thermo Fisher anticipates that Solventum’s Purification & Filtration business will contribute to mid to high-single-digit organic growth and drive strong margin expansion. Marc N. Casper, Chairman, President and Chief Executive Officer of Thermo Fisher, said, “Solventum’s portfolio of solutions will be valued by our customers, and further demonstrate our disciplined capital deployment strategy which has an excellent track record of creating shareholder value.”
